FDA Approves First Drug Treatment for Postpartum Depression [Fortune]
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Fortune
FDA Approves First Drug Treatment for Postpartum Depression The U.S. Food and Drug Administration (FDA) has approved a drug for the first time that aims at treating postpartum depression in mothers. Dubbed Zulresso, the medication is administered by a continuous intravenous (IV) infusion for 60 hours. According to the FDA Despite those concerns, the FDA found Zulresso, which is owned by Sage Therapeutics, to be effective in Postpartum depression is a major depressive disorder that can affect women both during pregnancy and after childbirth. It’s often associated with varying levels of sadness, an inability to feel pleasure, and in severe cases, suicidal thoughts. In some cases, mothers may have thoughts of harming their children. Whether Zulresso will actually be used in widespread cases remains to be seen. The 60-hour treatment window in a healthcare facility for a mother who’s raising one or more children might be difficult to accommodate.
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $21.00 to $17.00. They now have a "hold" rating on the stock.MarketBeat
- Sage Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]Yahoo! Finance
- INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress [Yahoo! Finance]Yahoo! Finance
SAGE
Earnings
- 4/25/24 - Miss
SAGE
Sec Filings
- 4/25/24 - Form 10-Q
- 4/25/24 - Form 8-K
- 4/24/24 - Form ARS
- SAGE's page on the SEC website